Loading...
Speciality Medicines Limited — Nivolumab Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #5 for Nivolumab · $28.6K export value · DGFT Verified
Speciality Medicines Limited is the #5 Indian exporter of Nivolumab with $28.6K in export value and 10 verified shipments. Speciality Medicines Limited holds a 1.3% market share in Nivolumab exports across 1 countries. The company exports 6 pharmaceutical products worth $345.1K across 2 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| SINGAPORE | $800.0K | 16 | 48.2% |
| RUSSIA | $400.0K | 8 | 24.1% |
| BRAZIL | $280.5K | 59 | 16.9% |
| SEYCHELLES | $56.6K | 6 | 3.4% |
| MALDIVES | $54.8K | 12 | 3.3% |
| JAPAN | $28.7K | 15 | 1.7% |
| UNITED KINGDOM | $20.9K | 4 | 1.3% |
| BRITISH VIRGIN ISLANDS | $5.7K | 1 | 0.3% |
| UNITED STATES | $4.9K | 10 | 0.3% |
| GERMANY | $4.4K | 9 | 0.3% |
India exports Nivolumab to 13 countries. The top destination is SINGAPORE (48.2%), followed by RUSSIA and BRAZIL.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| COREX LLC | RUSSIA | $400.0K | 8 |
| ALMAC PHARMACEUTICAL SERVICES PTE LIMITED | SINGAPORE | $100.0K | 2 |
| AS PER INVOICE | BRAZIL | $72.9K | 7 |
| STATE TRADING ORGANIZATION PLC | MALDIVES | $32.3K | 6 |
| JAIR CARLOS DE ARAUJO | BRAZIL | $30.5K | 4 |
| HEALTH CARE AGENCY | SEYCHELLES | $21.7K | 2 |
India exported $946.0K worth of Nivolumab through 144 shipments from 23 suppliers to 13 countries, serving 47 buyers globally. Speciality Medicines Limited contributes $28.6K to this total, accounting for 1.3% of India's Nivolumab exports.
Speciality Medicines Limited's average Nivolumab shipment value is $2.9K per consignment, based on 10 shipments totaling $28.6K.
Speciality Medicines Limited ranks #5 among 23 Indian Nivolumab exporters with a 1.3% market share. The top 3 exporters are DR.REDDY'S LABORATORIES LTD ($577.4K), CORSANTRUM TECHNOLOGY ($115.1K), VAMA LIFECARE PRIVATE LIMITED ($72.9K). Speciality Medicines Limited processed 10 shipments to 1 destination countries.
What Speciality Medicines Limited must comply with to export Nivolumab to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | VAMA LIFECARE PRIVATE LIMITED | $72.9K | 7 | 1 | $10.4K |
| 4 | MODERN DRUG HOUSE | $28.7K | 15 | 1 | $1.9K |
| 5 | SPECIALITY MEDICINES LIMITED ★ | $28.6K | 10 | 1 | $2.9K |
| 6 | RBN MEDITECH PRIVATE LIMITED | $28.4K | 12 | 1 | $2.4K |
| 7 |
| Port | Shipments | % Share |
|---|---|---|
| AHEMDABAD AIR ACC (INAMD4) | 38 | 26.4% |
| SAHAR AIR | 27 | 18.8% |
| AHEMDABAD AIR | 15 | 10.4% |
| HYDERABAD AIR | 11 | 7.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 11 | 7.6% |
| Ahmedabad Air | 8 | 5.6% |
| CHENNAI AIR CARGO ACC (INMAA4) | 5 | 3.5% |
| BANGALORE ACC (INBLR4) | 5 | 3.5% |
Speciality Medicines Limited also exports these advanced oncology products. Each links to the detailed product page.
Speciality Medicines Limited exports 6 products worth $345.1K. Beyond Nivolumab, top products include Pembrolizumab, Olaparib, Ustekinumab, Lenvatinib, Cabozantinib. View the complete Speciality Medicines Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Nivolumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Speciality Medicines Limited's Nivolumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Speciality Medicines Limited
Full Company Profile →
6 products · $345.1K total trade · 2 categories
| INDIRA GANDHI MEMORIAL HOSPITAL |
| MALDIVES |
| $12.0K |
| 5 |
| FRANCISCO EUDES DA SILVA | BRAZIL | $11.8K | 2 |
| ELIZETE DE OLIVEIRA DA SILVA | BRAZIL | $11.8K | 4 |
| INVOICE RAISED TO SEYCHELLES | SEYCHELLES | $11.8K | 2 |
India's Nivolumab is purchased by 47 buyers worldwide. The top buyer is COREX LLC (RUSSIA), followed by ALMAC PHARMACEUTICAL SERVICES PTE LIMITED and AS PER INVOICE.
| VEA IMPEX I PRIVATE LIMITED |
| $27.9K |
| 4 |
| 3 |
| $7.0K |
Speciality Medicines Limited ranks #5 among 23 Indian Nivolumab exporters. Average shipment value of $2.9K compared to the market average of $41.1K. The closest competitors by value are VAMA LIFECARE PRIVATE LIMITED and MODERN DRUG HOUSE.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 13+ countries, 47+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Speciality Medicines Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Nivolumab. For current shipment-level data, contact TransData Nexus.